Cargando…

Clinical outcomes, not clinical utility, should be the major consideration for saxagliptin with or without metformin

Detalles Bibliográficos
Autor principal:	Doggrell, Sheila A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3999272/ https://www.ncbi.nlm.nih.gov/pubmed/24790414 http://dx.doi.org/10.2147/PPA.S63080

Ejemplares similares

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2011)

Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
por: Panagoulias, George S, et al.
Publicado: (2014)

Exenatide extended-release; clinical trials, patient preference, and economic considerations
por: Doggrell, Sheila A
Publicado: (2013)

Not so critical appraisal of dapagliflozin
por: Doggrell, Sheila A
Publicado: (2014)

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
por: Minze, Molly G., et al.
Publicado: (2013)

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
por: Neutel, Joel M., et al.
Publicado: (2013)

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
por: Pollack, Pia S., et al.
Publicado: (2017)

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Kombiglyze (metformin and saxagliptin)‐induced hepatotoxicity in a patient with non‐alcoholic fatty liver disease
por: Thalha, Abdul Malik, et al.
Publicado: (2018)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Clinical utility and patient considerations in the use of the sitagliptin–metformin combination in Chinese patients
por: Du, Qiang, et al.
Publicado: (2015)

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
por: Jain, Rajeev
Publicado: (2015)

Clinically relevant reductions in HbA(1c) without hypoglycaemia: results across four studies of saxagliptin
por: Karyekar, C S, et al.
Publicado: (2013)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial
por: Dore, Fiona J., et al.
Publicado: (2018)

Saxagliptin for type 2 diabetes
por: Chacra, Antonio R
Publicado: (2010)

No apparent association between lecture attendance or accessing lecture recordings and academic outcomes in a medical laboratory science course
por: Doggrell, Sheila Anne
Publicado: (2020)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin
por: Kenawy, Sara, et al.
Publicado: (2017)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
por: Johansson, Lars, et al.
Publicado: (2020)

Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials
por: Sjöstrand, Mikaela, et al.
Publicado: (2017)

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2020)

Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia
por: Bekele, Mengistu, et al.
Publicado: (2021)

Lyprinol—Is It a Useful Anti-Inflammatory Agent?
por: Doggrell, Sheila A.
Publicado: (2011)

Exenatide at mealtimes in type 1 diabetes—no MAG1C with exenatide, or with other glucagon-like peptide-1 receptor agonists
por: Doggrell, Sheila A.
Publicado: (2020)

Follow-up descriptive study of how proportioning marks between coursework and examination affects the performance of students in nursing
por: Doggrell, Sheila A
Publicado: (2023)

Evaluation of drug interactions of saxagliptin with sildenafil in healthy volunteers
por: Mansour, Rania Y., et al.
Publicado: (2022)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
por: White, Judith L, et al.
Publicado: (2014)

Valve positions upon which cardiac surgeons operate should be taken into consideration
por: Wang, Tsu-Hsien, et al.
Publicado: (2023)

Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Liu, Hao, et al.
Publicado: (2016)

Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment
por: Tao, Tao, et al.
Publicado: (2018)

Can nutritional interventions change major clinical outcomes?
por: Horikita, Sho, et al.
Publicado: (2018)

Descriptive study of how proportioning marks determines the performance of nursing students in a pharmacology course
por: Doggrell, Sheila Anne
Publicado: (2020)

Careful consideration should be paid in the new imaging modality evaluation
por: Sekine, Tetsuro, et al.
Publicado: (2021)

Comparison of charges and resource use associated with saxagliptin and sitagliptin
por: Vaidya, Varun, et al.
Publicado: (2016)

Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II
por: Torre, Enrico, et al.
Publicado: (2020)

Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes
por: Mathieu, Chantal, et al.
Publicado: (2018)

Combined Intranasal Insulin/Saxagliptin/Metformin Therapies Ameliorate the Effect of Combined Oral Contraceptive- (COC-) Induced Metabolic Syndrome (MetS) with a Major Target on Glucose Metabolism in Adult Female Wistar Rats
por: Afolabi, Saheed Olanrewaju, et al.
Publicado: (2021)

COVID-19: should oral vaccination strategies be given more consideration?
por: Mehan, Aman, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_acon9pf9vg7nanmtrm27bv0ur1